On August 16, 2018, Ivantis, Inc. (“Defendant”) filed an Answer with Counterclaims against Glaukos Corporation (“Plaintiff”). In the Answer, the Defendant denies all of the infringement claims being asserted against them, namely, that the Defendant is infringing U.S. Patent Nos. 6,626,858 and 9,827,143, which are drawn to shunt devices and methods of treating ocular disorders (e.g., glaucoma). The Defendant further asserts, in the Answer, that the Plaintiff is infringing U.S. Patent Nos. 8,540,659 (“the ‘659 Patent”), 9,603,741 (“the ‘741 Patent”), and 9,833,357 (“the ‘357 Patent”), which are assigned to the Defendant, and are drawn to an intraocular implant device and method of use for the eye. The Defendant is asserting that the Plaintiff is infringing the ‘659 Patent, the ‘741 Patent, and the ‘357 Patent by making, using, offering for sale, selling, and/or importing intraocular implant products, including the iStent inject product of the Plaintiff. The case remains pending and is captioned 8-18-cv-00620.
By: Jacqueline A. DiRamio